ABOUT US

The human microbiota can be regarded as an additional organ per se and performs a wide range of functions, from facilitating the digestion to producing vitamins, modulating the risk of metabolic diseases and helping shape the immune system. However, extensive use of antibiotics and disinfectants in modern societies, as well as dietary changes, have resulted in a significant decline of microbiota diversity.
 

AB-Biotics identified areas where modern lifestyle has had little impact and thus the original microbiota has been preserved. These areas are known to display a low incidence of immune and metabolic disorders, an observation that led to the development of the “hygiene hypothesis”.  As a consequence, AB-Biotics conducted several expeditions to isolate  Lactic Acid Bacteria Strains from healthy individuals living in those areas, in order to build a strains bank composed of “microbial old friends” whose numbers are declining in the microbiotas of people living in modern societies.
 

Currently, AB-Biotics owns a strains bank with a collection of more than 550 different wild-type strains of human origin sampled from different areas in the world.

Overview

AB-Biotics was founded by Miquel Angel Bonachera and Sergi Audivert in 2004. Both students at the Universitat Autònoma de Barcelona (UAB), in 2004. The company was started with two technology platforms:

 

— Research and development of probiotics, based on its own collection of 550 strains.

— Development of advanced genetic tools for healthcare providers.

Team

The AB-BIOTICS team comprises professionals with expertise in different disciplines, including biotechnology, microbiology, genetics, biochemistry, chemistry and bioinformatics, providing us with broad technical knowledge and skills.

Vision & Mision

Vision: AB-Biotics aspires to set a standard in the European biotechnology industry for both Microbiome Modulators and Personalized Medicine.


Mision: AB-Biotics strives to improve health by developing products and providing services that help support healthy living and prevent diseases.

PRODUCTS

PROBIOTICS

THE BEST POSSIBLE STRAIN TO GUARANTEE THE BEST CLINICAL EFFECT

READ MORE
Cardiometabolic

AB-Life

Probiotic formula which reduces total cholesterol levels by 12% on average, according to published clinical data.
READ MORE
AB-Life

AB Life Forte

Probiotic formula combining AB-Life strains and Monacolin K to enhance total cholesterol and LDL-cholesterol reduction.
READ MORE
AB Life Forte

AB-Life Plus

Probiotic formula combining AB-Life strains and an omega-3 source (Alpha-Linolenic Acid) to enhance total cholesterol, LDL-cholesterol and Triglycerides reduction.
READ MORE
AB-Life Plus

LipiGO

Patented weight management solution based on brewer’s yeast cell wall functional extract with selective fat binding properties.
READ MORE
LipiGO
Oral Care

AB-Dentalac

The first probiotic specifically designed to fight the oral pathogens causing the most common oral diseases: caries, gingivitis and bad breath.
READ MORE
AB-Dentalac

AB-Dentalac Pro

The first probiotic therapy specifically designed for dentists against the most common oral pathogens causing caries, gingivitis and bad breath. 

READ MORE
AB-Dentalac Pro

AB-Dentalac Junior

The first probiotic specifically designed to fight the oral pathogens causing the most common oral diseases: caries, gingivitis and bad breath in children.

READ MORE
AB-Dentalac Junior

AB-Dentisanium

Probiotic formula which acts as a shield against caries, preventing the growth of caries-associated bacteria.

READ MORE
AB-Dentisanium
Pediatrics

AB-Kolicare

Probiotic formula for the treatment of infantile colic, which significantly reduces excessive crying in colicky infants according to clinical data.

READ MORE
AB-Kolicare

AB-Digest Kids

Probiotic formula with prebiotics and Zinc for acute treatment and recovery from diarrhea episodes in children.

READ MORE
AB-Digest Kids
Gastrointestinal Health

i3.1

Effective relief of the Irritable Bowel Syndrome (IBS)
READ MORE
i3.1
Gynaecology & Urology

AB-Intimus

Probiotic useful to prevent vaginal infection recurrence, able to survive in an inflamed vaginal mucosa and restore the vaginal ecosystem and a healthy vaginal pH. It can be used in co-therapy treatments with anti-mycotics. Available in different dosage forms (Vaginal tablets, vaginal capsules and oral capsules).

READ MORE
AB-Intimus

AB-Cyscare

Probiotic formula with lactic acid bacteria and cranberry extract for treating and preventing recurrent urinary tract infections (UTI) such as cystitis.

READ MORE
AB-Cyscare
Dermatology & Immunology

AB-Immuno

Probiotic formula with a specific functional effect for maintaining digestive health, enhancing systemic immunity and stimulating immunoglobulin production.

READ MORE
AB-Immuno

AB-Sakei 65

Probiotic formula for treatment and prevention of atopic dermatitis.

READ MORE
AB-Sakei 65
Probiotics pipeline

GENETIC TESTS

IDENTIFYING THE MOST SUITABLE SOLUTION FOR EACH PATIENT

READ MORE
Genetic tests pipeline

LAB SERVICES

Personalized Medicine & Genetics
Personalized Medicine & Genetics
Personalized Medicine & Genetics

AB-Biotics laboratory is a private molecular genetics laboratory renowned for its pioneering work in genomic testing and the commercialization of Neuropharmagen, a CNS disorders personalized medicine platform that combines pharmacogenetics with drug pharmacokinetics, drug pharmacodynamics, comorbidity and environmental factors in a single interface for its use in psychiatry and neurology that assures the safest and most appropriates medication for each patient.

 

In addition to we recently implemented  genetic tests in the fertility and pain treatment fields. But working in the development of new fields such as Endometriosis, or certain types of specific Oncology testing.

 

Nonetheless AB-BIOTICS is combining its genetics R&D with its microbiome R&D teams in order to develop metagenomic tests to tackle personalized microbiome modulators.  

 

We offer a wide range of genomic services which allows us to help our clients select the best solution to meet their business needs. AB-Biotics laboratory has based its strength on its level of equipment with the latest technology available allowing us to reduce costs and to become more competitive. Our staff includes phD scientists expertise in genetics which can guide you through every phase of your project.


Moreover, AB-Biotics also offers its expertise on bioinformatics to help get the most of genetic data. By means of its expertise on machine learning algorithms (such as multifactor dimensionality reduction, support vector machines or decision trees), AB-Biotics is able to identify multigene signatures that can display markedly enhanced predictive power compared both to single genes and to multigenic scores based solely on additivity. Machine learning algorithms are better suited to identify predictive signatures from sparse and incomplete datasets than traditional univariate and multivariate statistics, especially when several genetic variants are involved in a given trait and the presence of a variant in one locus can synergize or can nullify the effect of a variant in a second locus. 

READ MORE
Microbiology & Microbiome Modulators.
Microbiology & Microbiome Modulators.
Microbiology & Microbiome Modulators.

AB-Biotics has developed a wide range of clinically documented probiotics to reduce the risk of cardiovascular disease (AB-LIFE), reduce the burden of gastroinestinal alterations in patients affected by IBD and IBS (I3.1), prevent the recurrence of vaginal Candida infections (AB-INTIMUS), treat infant colic (AB-Colic), displace oral pathogens causing caries, gingivitis and halitosis or bad breath (AB-Dentisanium), etc.


During the latest years AB-BIOTICS research activities have been focusing in exhaustive metagenomic analysis of human body’s microbiomes in order to find microbiome modulators aimed at improving the human microbiota to reduce the risk of dysbiosis-related diseases such as Caries or CDI infections. 
READ MORE

NEWS

The AB-Biotics Personalized Medicine Platform (NEUROFARMAGEN) Increases Psychiatric Treatment Efficacy by 67%
As part of the European College of Neuropsychopharmacology (ECNP), the biotechnology company AB-Biotics presented a study showing that patients with major depressive disorder following therapies based on pharmacogenetics improve their response to medication.

READ MORE
UIC Barcelona y AB-Biotics se unen para investigar en el ámbito de los probióticos
UIC Barcelona y AB-Biotics se unen para investigar en el ámbito de los probióticos
UIC Barcelona y AB-Biotics se unen para investigar en el ámbito de los probióticos
READ MORE
AB Biotics completes its Board of Directors by naming two independent members

- By incorporating Josep Maria Echarri, Managing Director of Inveready Asset Management, and Joan Ramón Ramos, a renowned economist with a long trajectory in the world of business consultancy, AB Biotics completes the new structure of its Board of Directors and corporate government.



- The Board also counts with Sergi Audivert and Miquel Àngel Bonachera, in the role of executive board member, and four representatives of Kaneka, as well as Luís Sánchez-Lafuente

READ MORE
AB Biotics renews its Board of Directors to begin a new cycle
- Yesterday’s Annual General Meeting of Shareholders named the members of the new Board of Directors
- The founding partners are now joined by Luís Sánchez-Lafuente and four board members from Kaneka Corporation, all of whom are dominical
- The two founding partners, Sergi Audivert and Miquel Àngel Bonachera, together with Luis Sánchez-Lafuente and Kaneka Corporation, currently represent 67.62% of the shareholding
- The new Board of Directors will now convene the ordinary AGM of Shareholders, which has been pending since the resignations of former members on May 29th
READ MORE
AB-Biotics incrementa las ventas un 82% en 2017
  • La biotecnológica se consolida en 2017, supera con solvencia los objetivos y alcanza un importe neto de la cifra de negocios de 7.207.694 de euros
  • El negocio de probióticos de la compañía ha liderado el fuerte crecimiento del negocio orgánico de la compañía.
  • La estrategia implementada en marzo de 2017 ha supuesto una mayor eficiencia en operaciones y una fuerte reducción de costes: en consecuencia, la compañía ha entrado en EBITDA positivo y flujo de caja positivo desde el último trimestre de 2017.
READ MORE
Meet us at “International meeting on personalized medicine in psychiatry” in Pisa, June 8th at 10:30h, and discuss with our geneticist Dr. Miquel Tuson, about the "Lessons from the AB-GEN  randomized multicentric trial on practical pharmacogenetics in maj
Meet us at “International meeting on personalized medicine in psychiatry” in Pisa, June 8th at 10:30h, and discuss with our geneticist Dr. Miquel Tuson, about the "Lessons from the AB-GEN  randomized multicentric trial on practical pharmacogenetics in maj
Meet us at “International meeting on personalized medicine in psychiatry” in Pisa, June 8th at 10:30h, and discuss with our geneticist Dr. Miquel Tuson, about the "Lessons from the AB-GEN  randomized multicentric trial on practical pharmacogenetics in maj
READ MORE
AB-Biotics finalizes a study that supports the probiotic AB-Kolicare® to reduce crying caused by colic of the infant
AB-Biotics shows new and promising clinical evidence on the use of its probiotic AB-Kolicare® in the treatment of childhood colic.

The disorder accounts for between 10% and 20% of pediatric visits in the first 4 months of a baby's life.
READ MORE
17-10-2018

The AB-Biotics Personalized Medicine Platform (NEUROFARMAGEN) Increases Psychiatric Treatment Efficacy by 67%

As part of the European College of Neuropsychopharmacology (ECNP), the biotechnology company AB-Biotics presented a study showing that patients with major depressive disorder following therapies based on pharmacogenetics improve their response to medication.

READ MORE
13-08-2018

AB Biotics completes its Board of Directors by naming two independent members

- By incorporating Josep Maria Echarri, Managing Director of Inveready Asset Management, and Joan Ramón Ramos, a renowned economist with a long trajectory in the world of business consultancy, AB Biotics completes the new structure of its Board of Directors and corporate government.


 
- The Board also counts with Sergi Audivert and Miquel Àngel Bonachera, in the role of executive board member, and four representatives of Kaneka, as well as Luís Sánchez-Lafuente

 

READ MORE
30-04-2018

AB-Biotics incrementa las ventas un 82% en 2017

READ MORE
18-09-2018

UIC Barcelona y AB-Biotics se unen para investigar en el ámbito de los probióticos

La Universidad y la empresa líder en biotecnología han firmado un acuerdo de colaboración para trabajar conjuntamente en el programa "Polyphosphate and Probiotic mechanism of action"
READ MORE
05-07-2018

AB Biotics renews its Board of Directors to begin a new cycle

- Yesterday’s Annual General Meeting of Shareholders named the members of the new Board of Directors
- The founding partners are now joined by Luís Sánchez-Lafuente and four board members from Kaneka Corporation, all of whom are dominical
- The two founding partners, Sergi Audivert and Miquel Àngel Bonachera, together with Luis Sánchez-Lafuente and Kaneka Corporation, currently represent 67.62% of the shareholding
- The new Board of Directors will now convene the ordinary AGM of Shareholders, which has been pending since the resignations of former members on May 29th
READ MORE
20-07-2017

AB-Biotics successfully demonstrates the efficacy of a probiotic against gingivitis

  • AB-Biotics presenta nuevas y robustas evidencias clínicas sobre el uso de su probiótico AB-Dentalac® Gum en el tratamiento de la gingivitis.
  • La eficacia de los probióticos para el combate de enfermedades goza, cada vez más, de mayor evidencia científica, según destaca el profesor Mariano Sanz, investigador principal del estudio.
  • La eliminación mecánica de la placa por parte de un profesional y una correcta higiene de cepillado diario reduce, pero no elimina, las bacterias dañinas; mientras que añadir ciertas bacterias beneficiosas para mejorar el equilibrio del microbioma oral puede reducir la inflamación de las encías.
READ MORE
1 2 3 4 5 6 7 8 9 10 11 12 13 14

INVESTORS

Relevant information and others of interest to investors
31/10/2018 - 18:08

Hecho Relevante: Composición del consejo de administración - Dimisión de Consejero

READ MORE
08/10/2018 - 11:50

Hecho Relevante: Composición de otros órganos de gestión y control - Nombramiento del Presidente de la Comisión de Auditoría y de la Comisión de Nombramientos y Retribuciones

READ MORE
29/08/2018 - 13:34

Hecho Relevante: Composición de otros órganos de gestión y control - Acuerdos del Consejo de Administración. Constitución de la Comisión de Auditoría y de la Comisión de Nombramientos y Retribuciones

READ MORE